▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3769 by analyst upside · 2026-11-13
BMY
Bristol-Myers Squibb Company
Healthcare · Market Cap $127B · P/E 13.8x
ANALYST PRICE TARGET
+4.7%
implied upside to consensus target
Current Price $62.32
Consensus Target $65.25
Bull Target $80.0
Bear Target $40.0
Analysts Covering 24
ANALYST CONSENSUS - HOLD
Strong Buy
3
Buy
5
Hold
15
Sell
1
52-Week Low $45.27
52-Week High $68.64
YTD Return +20.3%
FUNDAMENTALS
Market Cap $127B
P/E Ratio (TTM) 13.8x
Forward P/E 9.3x
EPS (TTM) $4.51
PEG Ratio 17.25
Dividend Yield 4.04%
Revenue (TTM) $50.0B
Profit Margin 18.5%
52-WEEK RANGE
52-Week Low $45.27
52-Week High $68.64
Current Price $62.32
Bear Target $40.0
Bull Target $80.0
● Now $62.32 ● Target $65.25
TRADING DATA
Avg Volume 10.9M
YTD Return +20.3%
Analyst Count 24
Consensus Hold
Upside to Target +4.7%
Last Updated 2026-11-13

ANALYST SUMMARY

Bristol-Myers Squibb Company (BMY) is currently trading at $62.32 with a Wall Street consensus price target of $65.25, implying potential upside of 4.7% over the next 12 months. 24 analysts currently cover BMY, with a consensus rating of Hold - 33% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $80.0, while the most cautious has a target of $40.0.

BMY operates in the Healthcare sector with a market capitalisation of $127B. The stock is up 20.3% year-to-date and is currently trading near the upper end of its 52-week range of $45.27 – $68.64.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ZTS +8.1%
Zoetis Inc.
$34B · P/E 14.1x · Buy
INCY +8.1%
Incyte Corporation
$25B · P/E 62.1x · Buy
PFE +4.8%
Pfizer Inc.
$164B · P/E 41.2x · Hold
OMCL +64.3%
Omnicell, Inc.
$2B · P/E 36.4x · Buy
GMAB +25.8%
Genmab A/S
$32B · P/E 44.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BMY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley - Reiterated
Underweight → Underweight 2026-10-30 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-10-26 14% win rate (7 calls)
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-10-13 Building track record
Cantor Fitzgerald - Reiterated
Neutral → Neutral 2026-10-08 40% win rate (10 calls)
Morgan Stanley - Reiterated
Underweight → Underweight 2026-10-07 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-10-05 29% win rate (7 calls)
Piper Sandler reit
Overweight → Overweight 2026-09-16 14% win rate (7 calls)
HSBC - Reiterated
Hold → Hold 2026-09-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
25/30
Consensus clarity
17/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →